# A Single and Repeat Dose PK/PD Study to Characterise Biomarker Response in Healthy Subjects Treated With Azithromycin

> **NCT01416350** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 20 (actual)

## Conditions studied

- Autoimmune Diseases

## Interventions

- **DRUG:** Azithromycin - 250 mg
- **DRUG:** Azithromycin - 1000 mg
- **DRUG:** Azithromycin - 250 mg every other day for 3 weeks

## Key facts

- **NCT ID:** NCT01416350
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-30
- **Primary completion:** 2011-05-12
- **Final completion:** 2011-05-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01416350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01416350, "A Single and Repeat Dose PK/PD Study to Characterise Biomarker Response in Healthy Subjects Treated With Azithromycin". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01416350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*